Emerging Role of Aurora Kinase Inhibitors in Chronic Myeloid Leukemia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Leukemia

• Publication date

  2007-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3816/CLK.2007.N.025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

  2007cited by this paper
• MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

  2007cited by this paper
• Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

  2007cited by this paper
• Contributions of the kinase cross-reactivity profile of MK-0457 to clinical activity

  2007cited by this paper
• Aurora kinases A and B and familial breast cancer risk.

  2007cited by this paper
• Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

  2007cited by this paper
• Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

  2007cited by this paper
• MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy

  2007cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

  2007cited by this paper
• MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

  2006cited by this paper
• Targeted CML therapy: controlling drug resistance, seeking cure.

  2006cited by this paper
• Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

  2006cited by this paper
• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  2006cited by this paper
• Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

  2006cited by this paper
• Synergistic Activity of the Aurora Kinase Inhibitor MK-0457 (VX-680) with Idarubicin, Ara-C, and Inhibitors of BCR-ABL.

  2006cited by this paper
• Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

  2006cited by this paper
• MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

  2006cited by this paper
• Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

  2006cited by this paper
• MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

  2006cited by this paper
• Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152.

  2006cited by this paper
• Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

  2005cited by this paper
• Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

  2005cited by this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.

  2005cited by this paper
• A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec).

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53

  2004cited by this paper
• Aurora B expression in normal testis and seminomas.

  2004cited by this paper
• Oncogenes and Tumor Suppressors (795 articles)

  2004cited by this paper
• Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation

  2003cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• The cellular geography of Aurora kinases

  2003cited by this paper
• Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.

  2003cited by this paper
• Functional significance of the specific sites phosphorylated in desmin at cleavage furrow: Aurora-B may phosphorylate and regulate type III intermediate filaments during cytokinesis coordinatedly with Rho-kinase.

  2003cited by this paper
• Aurora-B Regulates the Cleavage Furrow-specific Vimentin Phosphorylation in the Cytokinetic Process*

  2003cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis.

  2003cited by this paper
• The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis.

  2002cited by this paper
• Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A

  2002cited by this paper
• Human TPX2 is required for targeting Aurora-A kinase to the spindle

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis

  2002cited by this paper
• Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases

  2002cited by this paper
• Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

  2002cited by this paper
• APC/Fizzy‐Related targets Aurora‐A kinase for proteolysis

  2002cited by this paper
• Cell division: Mitotic kinases as regulators of cell division and its checkpoints

  2001cited by this paper
• Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation

  2001cited by this paper
• Chromosomal passengers and the (aurora) ABCs of mitosis.

  2001cited by this paper
• Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers

  2001cited by this paper
• Chromatin-associated Protein Phosphatase 1 Regulates Aurora-B and Histone H3 Phosphorylation*

  2001cited by this paper
• Roots of clinical resistance to STI-571 cancer therapy.

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Essential Roles of Drosophila Inner Centromere Protein (Incenp) and Aurora B in Histone H3 Phosphorylation, Metaphase Chromosome Alignment, Kinetochore Disjunction, and Chromosome Segregation

  2001cited by this paper
• Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.

  2001cited by this paper
• Downregulation of an Aim-1 Kinase Couples with Megakaryocytic Polyploidization of Human Hematopoietic Cells

  2001cited by this paper
• Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway

  2000cited by this paper
• Myosin II regulatory light chain as a novel substrate for AIM-1, an aurora/Ipl1p-related kinase from rat.

  2000cited by this paper
• Centrosomal Kinases, HsAIRK1 and HsAIRK3, are Overexpressed in Primary Colorectal Cancers

  2000cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

  2000cited by this paper
• The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation

  2000cited by this paper
• Mitotic kinase expression and colorectal cancer progression.

  1999cited by this paper
• Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast.

  1999cited by this paper
• Chronic myelogenous leukemia: update on biology and treatment.

  1999cited by this paper
• AIM‐1: a mammalian midbody‐associated protein required for cytokinesis

  1998cited by this paper
• Protein Kinase Profile of Sperm and Eggs: Cloning and Characterization of Two Novel Testis-Specific Protein Kinases (AIE1, AIE2) Related to Yeast and Fly Chromosome Segregation Regulators

  1998cited by this paper
• A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

  1998cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Type 1 protein phosphatase acts in opposition to IpL1 protein kinase in regulating yeast chromosome segregation

  1994cited by this paper

• Novel therapeutic approaches in chronic myeloid leukemia.

  2020cites this paper
• Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

  2018cites this paper
• CCT137690, Inhibitor of Aurora Kinase, Can Stimulate Apoptosis in Chronic Myeloid Leukemia Cells

  2017cites this paper
• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  2010cites this paper